Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2020 5
2021 11
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Revisiting the Use of Deep Temporalis Fascia Grafts in Ophthalmology.
Razlog E, Denoyer A, Baillif S, Arndt C, Dubernard X, Caujolle JP, Nahon-Esteve S, Martel A. Razlog E, et al. Among authors: nahon esteve s. Semin Ophthalmol. 2024 Apr 25:1-9. doi: 10.1080/08820538.2024.2346756. Online ahead of print. Semin Ophthalmol. 2024. PMID: 38661124
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.
Proteau S, Krossa I, Husser C, Guéguinou M, Sella F, Bille K, Irondelle M, Dalmasso M, Barouillet T, Cheli Y, Pisibon C, Arrighi N, Nahon-Estève S, Martel A, Gastaud L, Lassalle S, Mignen O, Brest P, Mazure NM, Bost F, Baillif S, Landreville S, Turcotte S, Hasson D, Carcamo S, Vandier C, Bernstein E, Yvan-Charvet L, Levesque MP, Ballotti R, Bertolotto C, Strub T. Proteau S, et al. Among authors: nahon esteve s. EMBO Mol Med. 2023 Dec 7;15(12):e17719. doi: 10.15252/emmm.202317719. Epub 2023 Nov 15. EMBO Mol Med. 2023. PMID: 37966164 Free PMC article.
Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ, Lassalle S, Martel A, Nahon-Estève S, Macocco A, Zahaf K, Lalvee S, Fayada J, Lespinet-Fabre V, Bordone O, Pedeutour F, Baillif S, Hofman P. Lamas NJ, et al. Among authors: nahon esteve s. Pathology. 2023 Dec;55(7):929-944. doi: 10.1016/j.pathol.2023.08.003. Epub 2023 Sep 22. Pathology. 2023. PMID: 37863710 Free article.
Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical Practice.
Martel A, Mograbi B, Romeo B, Gastaud L, Lalvee S, Zahaf K, Fayada J, Nahon-Esteve S, Bonnetaud C, Salah M, Tanga V, Baillif S, Bertolotto C, Lassalle S, Hofman P. Martel A, et al. Among authors: nahon esteve s. Int J Mol Sci. 2023 Jul 4;24(13):11075. doi: 10.3390/ijms241311075. Int J Mol Sci. 2023. PMID: 37446253 Free PMC article.
Need for a Dedicated Ophthalmic Malignancy Clinico-Biological Biobank: The Nice Ocular MAlignancy (NOMA) Biobank.
Martel A, Gastaud L, Bonnetaud C, Nahon-Esteve S, Washetine K, Bordone O, Salah M, Tanga V, Fayada J, Lespinet V, Allegra M, Lalvee S, Zahaf K, Baillif S, Bertolotto C, Mograbi B, Lassalle S, Hofman P. Martel A, et al. Among authors: nahon esteve s. Cancers (Basel). 2023 Apr 19;15(8):2372. doi: 10.3390/cancers15082372. Cancers (Basel). 2023. PMID: 37190299 Free PMC article. Review.
[Current uveal melanoma treatments: Where do we stand ?].
Ch Papasotiriou E, Chessel E, Costa C, Daniel L, Deridder I, Garyga S, Gineste C, Nahon-Estève S. Ch Papasotiriou E, et al. Among authors: nahon esteve s. Med Sci (Paris). 2022 Aug-Sep;38(8-9):733-736. doi: 10.1051/medsci/2022112. Epub 2022 Sep 12. Med Sci (Paris). 2022. PMID: 36094247 Free article. French. No abstract available.
28 results